Hamilton Lane Advisors LLC decreased its holdings in shares of Intersect ENT Inc (NASDAQ:XENT) by 31.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,560 shares of the medical equipment provider’s stock after selling 10,000 shares during the quarter. Hamilton Lane Advisors LLC owned approximately 0.07% of Intersect ENT worth $699,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in XENT. Rhumbline Advisers lifted its holdings in shares of Intersect ENT by 5.9% during the second quarter. Rhumbline Advisers now owns 29,396 shares of the medical equipment provider’s stock worth $822,000 after buying an additional 1,625 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Intersect ENT by 23.0% during the second quarter. Bank of New York Mellon Corp now owns 185,117 shares of the medical equipment provider’s stock worth $5,174,000 after buying an additional 34,577 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Intersect ENT by 3.8% during the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after buying an additional 255 shares in the last quarter. Prudential Financial Inc. acquired a new stake in shares of Intersect ENT during the second quarter worth $229,000. Finally, Swiss National Bank lifted its holdings in shares of Intersect ENT by 23.7% during the second quarter. Swiss National Bank now owns 42,800 shares of the medical equipment provider’s stock worth $1,196,000 after buying an additional 8,200 shares in the last quarter. 86.31% of the stock is owned by institutional investors and hedge funds.
XENT has been the subject of a number of research reports. Northland Securities reissued a “hold” rating and set a $25.00 target price on shares of Intersect ENT in a report on Friday, November 3rd. BidaskClub downgraded Intersect ENT from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. JPMorgan Chase & Co. raised Intersect ENT from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Zacks Investment Research downgraded Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Finally, Canaccord Genuity reissued a “buy” rating and set a $36.00 target price on shares of Intersect ENT in a report on Monday, December 11th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Intersect ENT presently has a consensus rating of “Buy” and an average target price of $33.38.
In related news, CFO Jeryl L. Hilleman sold 12,835 shares of the business’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $33.81, for a total value of $433,951.35. Following the completion of the transaction, the chief financial officer now owns 25,767 shares of the company’s stock, valued at $871,182.27. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Gwen R. Carscadden sold 10,000 shares of the business’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $34.35, for a total value of $343,500.00. Following the completion of the transaction, the insider now directly owns 13,856 shares of the company’s stock, valued at approximately $475,953.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 116,886 shares of company stock valued at $3,663,594. 13.70% of the stock is owned by insiders.
Intersect ENT Inc (NASDAQ:XENT) traded up $0.15 during mid-day trading on Wednesday, reaching $33.95. The company had a trading volume of 228,632 shares, compared to its average volume of 316,318. The firm has a market capitalization of $1,000.00, a P/E ratio of -54.76 and a beta of 0.67. Intersect ENT Inc has a fifty-two week low of $11.75 and a fifty-two week high of $35.34.
Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. The business had revenue of $22.31 million during the quarter, compared to the consensus estimate of $21.53 million. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. Intersect ENT’s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. analysts predict that Intersect ENT Inc will post -0.63 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Hamilton Lane Advisors LLC Cuts Holdings in Intersect ENT Inc (XENT)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/17/hamilton-lane-advisors-llc-cuts-holdings-in-intersect-ent-inc-xent.html.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT Inc (NASDAQ:XENT).
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.